CG Oncology director sells exercised shares

CG Oncology, Inc. director James Mulay exercised a fully vested director stock option to acquire 24,165 shares of common stock at an exercise price of $26.63 per share.

Accepted by SEC EDGAR 07/14/2026 - 04:15 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

CG Oncology, Inc. director James Mulay exercised a fully vested director stock option to acquire 24,165 shares of common stock at an exercise price of $26.63 per share. He then sold 24,165 shares in an open-market transaction at a weighted average price of $75.16 per share.

The sales were executed under a Rule 10b5-1 trading plan adopted on March 27, 2026, with individual sale prices ranging from $74.98 to $75.79. After these transactions, this report shows 0 common shares and 0 related director stock options remaining in the reported accounts.

Insider Trade Summary 10b5-1

Exercise and Sale: 24,165 shares ($1.17M approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Mulay James

Role Director

Sold 24,165 shs ($1.82M)

Approx. gross sale proceeds $1.82M

Approx. exercise cost $644K

Approx. pre-tax spread $1.17M

Type	Security	Shares	Price	Value
Exercise	Director Stock Option (right to buy) F3	24,165	$0.00	$0.00
Exercise	Common Stock	24,165	$26.63	$644K
Sale	Common Stock F1, F2	24,165	$75.16	$1.82M

Holdings After Transaction: Director Stock Option (right to buy) — 0 contracts (Direct); Common Stock — 0 shares (Direct)

Footnotes (3)

1. F1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2026.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.98 to $75.79 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
3. F3. Fully vested.

Key Figures

Shares sold: 24,165 shares Weighted average sale price: $75.16 per share Sale price range: $74.98–$75.79 per share +5 more

8 metrics

Shares sold 24,165 shares Common stock sold in open-market transaction on 2026-07-10

Weighted average sale price $75.16 per share Average price for 24,165 shares sold on 2026-07-10

Sale price range $74.98–$75.79 per share Range of prices for multiple sale transactions on 2026-07-10

Option exercise shares 24,165 shares Shares acquired by exercising Director Stock Option on 2026-07-10

Option exercise price $26.63 per share Exercise price for Director Stock Option (right to buy)

Rule 10b5-1 plan adoption date March 27, 2026 Date James Mulay adopted the trading plan governing these sales

Option expiration date June 4, 2035 Original expiration date of the exercised Director Stock Option

Net shares sold 24,165 shares Net buy/sell shares from transaction summary (net-sell direction)

Key Terms

Rule 10b5-1 trading plan, weighted average price, Director Stock Option (right to buy), derivative security, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"The sales reported were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Director Stock Option (right to buy) financial

"security_title": "Director Stock Option (right to buy)""

derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CG Oncology (CGON) director James Mulay report?

Director James Mulay reported exercising a fully vested director stock option for 24,165 CG Oncology common shares at $26.63 per share, then selling the same 24,165 shares in an open-market transaction at a weighted average price of $75.16 per share.

How many CGON shares did James Mulay sell and at what price range?

James Mulay sold 24,165 CG Oncology common shares. The weighted average sale price was $75.16 per share, with individual trades executed at prices ranging from $74.98 to $75.79 per share, as disclosed in the transaction footnotes.

Were James Mulay’s CGON share sales made under a Rule 10b5-1 trading plan?

Yes. The filing states that Mulay’s sales were effected under a Rule 10b5-1 trading plan adopted on March 27, 2026. Such plans pre-schedule trades, indicating the timing of these sales was determined in advance rather than decided opportunistically.

What stock option did James Mulay exercise in this CGON filing?

Mulay exercised a fully vested Director Stock Option (right to buy) covering 24,165 shares of CG Oncology common stock at an exercise price of $26.63 per share. The option, which previously had an expiration date of June 4, 2035, is shown as fully exercised.

How many CGON shares does James Mulay hold after these reported transactions?

Following the reported exercise and sale, the Form 4 lists 0 shares of CG Oncology common stock and 0 director stock options remaining in the reported accounts. This reflects the full exercise and corresponding sale of the 24,165 shares covered by this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mulay James

(Last) (First) (Middle)

C/O CG ONCOLOGY, INC.

3000 PEGASUS PARK DRIVE, SUITE 1640

(Street)

DALLAS TEXAS 75247

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CG Oncology, Inc. [ CGON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/10/2026		M		24,165	A	$26.63	24,165	D
Common Stock	07/10/2026		S(1)		24,165	D	$75.16(2)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	$26.63	07/10/2026		M			24,165	(3)	06/04/2035	Common Stock	24,165	$0	0	D

Explanation of Responses:

1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2026.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.98 to $75.79 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

3. Fully vested.

	/s/ Joshua F. Patterson, Attorney-in-Fact for James J. Mulay	07/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)